drugset / Trial / NCT07639021

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

NCT07639021

Phase 2 Recruiting 230 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

Timeline

Start
2026-06-09
Primary completion
2027-07-12
Completion
2027-07-12

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0662-0419 Unknown Subcutaneous
Subject Semaglutide Peptide Subcutaneous

Indications